HyunHo Jung - Medy Tox CEO Director
| 086900 Stock | KRW 129,100 3,400 2.70% |
Insider
HyunHo Jung is CEO Director of Medy Tox
| Age | 61 |
| Phone | 82 4 3217 1555 |
| Web | https://www.medy-tox.co.kr |
Medy Tox Management Efficiency
The company has return on total asset (ROA) of 0.0304 % which means that it generated a profit of $0.0304 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.053 %, meaning that it generated $0.053 on every $100 dollars invested by stockholders. Medy Tox's management efficiency ratios could be used to measure how well Medy Tox manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jong Kim | ABL Bio | N/A | |
| Hyeok Gwon | SillaJen | 51 | |
| YeongGuk Cho | Woori Technology Investment | N/A | |
| Seungdo Lee | Woori Technology Investment | 58 | |
| Gyeong Hwang | SillaJen | 42 | |
| KiJoo Lee | Woori Technology Investment | N/A | |
| Byeong Kim | SillaJen | 51 | |
| Sang Lee | ABL Bio | N/A | |
| Seong Chi | SillaJen | 67 | |
| You WeonKyoo | ABL Bio | N/A | |
| Jong Won | ABL Bio | N/A | |
| Seok Kim | SillaJen | 39 | |
| Changman Chae | Woori Technology Investment | N/A | |
| Jong Park | SillaJen | 58 | |
| Hwan Sung | AptaBio Therapeutics | N/A | |
| Gyeong Ha | SillaJen | 45 | |
| Jeong Noh | SillaJen | 66 | |
| Gyeong Gook | SillaJen | 53 | |
| Junghoon Lee | Woori Technology Investment | 46 | |
| Hyeon Shin | SillaJen | 47 | |
| Jaecheon Lee | ABL Bio | N/A | |
Management Performance
| Return On Equity | 0.053 | |||
| Return On Asset | 0.0304 |
Medy Tox Leadership Team
Elected by the shareholders, the Medy Tox's board of directors comprises two types of representatives: Medy Tox inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medy. The board's role is to monitor Medy Tox's management team and ensure that shareholders' interests are well served. Medy Tox's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medy Tox's outside directors are responsible for providing unbiased perspectives on the board's policies.
| HeeSeok Joo, Managing Division | ||
| SeungBum Park, Head Director | ||
| HyunHo Jung, CEO Director | ||
| YongIn Kim, Managing Devel | ||
| KiHyuk Yang, MD Laboratory | ||
| Lopez Michael, Managing Office | ||
| WooSun Lee, Director Department |
Medy Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medy Tox a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.053 | |||
| Return On Asset | 0.0304 | |||
| Profit Margin | 0.13 % | |||
| Operating Margin | 0.16 % | |||
| Current Valuation | 989.66 B | |||
| Shares Outstanding | 5.44 M | |||
| Shares Owned By Insiders | 26.72 % | |||
| Shares Owned By Institutions | 10.75 % | |||
| Price To Earning | 57.74 X | |||
| Price To Sales | 3.96 X |
Pair Trading with Medy Tox
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medy Tox position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medy Tox will appreciate offsetting losses from the drop in the long position's value.Moving together with Medy Stock
Moving against Medy Stock
The ability to find closely correlated positions to Medy Tox could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medy Tox when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medy Tox - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medy Tox to buy it.
The correlation of Medy Tox is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medy Tox moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medy Tox moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medy Tox can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Medy Stock
Medy Tox financial ratios help investors to determine whether Medy Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medy with respect to the benefits of owning Medy Tox security.